z-logo
open-access-imgOpen Access
Emodin: Its role in prostate cancer‑associated inflammation (Review)
Author(s) -
Yanjie Tu,
Zhonghua Wu,
Bo Tan,
Aidong Yang,
Zhaoqin Fang
Publication year - 2019
Publication title -
oncology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.094
H-Index - 96
eISSN - 1791-2431
pISSN - 1021-335X
DOI - 10.3892/or.2019.7264
Subject(s) - molecular medicine , oncogene , prostate cancer , cancer , inflammation , emodin , prostate , cancer research , cell cycle , medicine , biology , oncology , biochemistry
Prostate cancer is one of the most common malignancies diagnosed in males. Cancer‑related inflammatory factors include tumor necrosis factor, inflammasomes, cytokines, chemokines, transcription factors, infiltrating or circulating immune cells, reactive oxygen species, and sex hormone receptors. These are mainly associated with the local immune response at the tumor site. Emodin, a chemical compound that can be isolated from the plant rhubarb among others, has been shown to exhibit anti‑inflammatory and anticancer properties in prostate cancer. This review summarizes the effects of emodin on prostate cancer and analyzes whether it interferes with prostate cancer through anti‑inflammatory pathways. New information regarding the development of emodin derivatives including their increased solubility and reduced side effects through chemical structure modifications is also reviewed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom